Knowledge HQ

This study develops affinity-tuned mesothelin (MSLN) CAR T cells to improve specificity and safety. Low-affinity variants showed effective tumor control with reduced off-tumor toxicity in mice. CAR T cells were expanded in G-Rex 6M well plates during the manufacturing process.

This study identifies an HLA-A*11:01-restricted TCR targeting KRAS G12V from a pancreatic cancer patient. T cells engineered with this TCR were expanded in G-Rex 24-well plates and showed specific recognition of tumor organoids, enhanced by IFN-gamma priming.

This study compares conventional and G-Rex systems for expanding BKPyV-specific T cells. G-Rex cultures resulted in higher total cell counts but increased PD-1 expression. The study highlights the need for optimization in adoptive T-cell therapy protocols for BKPyV.

This paper reports on BMS-986408, a dual DGK inhibitor that enhances PD-1 and CAR-T therapies. It improves T-cell signaling and effector function. CAR T cells were expanded in G-Rex 6M well plates during the manufacturing process for experimental assays.

This study demonstrates a process to manufacture Tumor-Associated Antigen-Specific T Cells (TAAT) by priming naïve T cells with MoDC directly in G-Rex devices. This closed-system approach eliminates the need for MoDC harvest and restimulation, yielding clinical doses from small blood volumes.

This abstract describes a streamlined protocol for manufacturing Monocyte-Derived Dendritic Cells (MoDC) using G-Rex devices. The method reduces cell loss associated with harvesting adherent cells and allows for the subsequent production of Tumor-Associated Antigen-Specific T Cells (TAAT) in the same vessel.

This study presents MARC, a modular CAR design that mimics native receptors to prevent tonic signaling and exhaustion. Primary T cells were transduced and expanded in 24-well G-Rex plates, demonstrating improved persistence and efficacy in leukemia models compared to traditional CARs.

This study introduces Cas9-CLIPT, a method to efficiently integrate large transgenes (2-6 kb) into human T cells without restriction enzymes. It produces highly potent GD2 TRAC-CAR T cells with an enriched stem cell memory phenotype. G-Rex 6M well plates are referenced for cell cultivation post-electroporation.

This study identifies PRDM1 as a key regulator of NKT cell central memory and effector function using CRISPR screening. PRDM1 knockdown preserved cytotoxicity and memory phenotype. NKT cells were expanded and restimulated in 6-well G-Rex plates during the protocol.

This poster describes a simplified CAR-T manufacturing method (Spo-T) using RetroNectin-coated G-Rex vessels. This approach allows simultaneous T-cell activation and transduction in a single vessel, showing higher proliferation and stemness compared to conventional methods.

This study identifies CSF1R+ myeloid-monocytic (LAMM) cells as drivers of CAR-T resistance in B-NHL. CSF1R inhibition combined with CAR-T therapy enhanced efficacy. Author H. Balke-Want received funding from the G-Rex Grant Program (Wilson Wolf), though specific device usage for main data is not detailed.

This study develops CD38KO/CD38-CAR γδT cells to treat T-cell malignancies, avoiding fratricide. A hybrid expansion protocol using G-Rex plates allowed robust expansion of polyclonal γδT cells. The edited cells showed potent anti-tumor activity in vitro and in vivo against T-ALL.